{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:43:21Z","timestamp":1793385801523,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04140-5","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:17:23Z","timestamp":1743484643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer\u2019s dementia continuum: an [18\u00a0F] AV-45 study"],"prefix":"10.1186","volume":"25","author":[{"given":"Rezvan","family":"Nemati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Sohrabi-Ashlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Saberian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-7876","authenticated-orcid":false,"given":"Mohammad","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mardani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Sina Jafari Hossein","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yaghoobpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Khoshroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassin","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-156X","authenticated-orcid":false,"given":"Mahsa","family":"Mayeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamide","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"4140_CR1","volume-title":"World alzheimer report 2015 - The global impact of dementia","author":"MJ Prince","year":"2015","unstructured":"Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World alzheimer report 2015 - The global impact of dementia. London: Alzheimer\u2019s Disease International; 2015."},{"issue":"1","key":"4140_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"4140_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4172\/pharmaceutical-sciences.1000397","volume":"80","author":"R Sajjad","year":"2018","unstructured":"Sajjad R, Arif R, Shah A, Manzoor I, Mustafa G. Pathogenesis of Alzheimer\u2019s disease: role of amyloid-beta and hyperphosphorylated Tau protein. Indian J Pharm Sci. 2018;80(4):581\u201391.","journal-title":"Indian J Pharm Sci"},{"issue":"3","key":"4140_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3233\/JAD-170680","volume":"62","author":"M Bjerke","year":"2018","unstructured":"Bjerke M, Engelborghs S. Cerebrospinal fluid biomarkers for early and differential Alzheimer\u2019s disease diagnosis. J Alzheimers Dis. 2018;62(3):1199\u2013209.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"4140_CR5","doi-asserted-by":"publisher","first-page":"a006270","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5):a006270.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"4140_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.15698\/cst2018.11.162","volume":"2","author":"H Steiner","year":"2018","unstructured":"Steiner H, Fukumori A, Tagami S, Okochi M. Making the final cut: pathogenic amyloid-\u03b2 peptide generation by \u03b3-secretase. Cell Stress. 2018;2(11):292.","journal-title":"Cell Stress"},{"issue":"7","key":"4140_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00044-021-02744-3","volume":"30","author":"MS Wolfe","year":"2021","unstructured":"Wolfe MS. Targeting \u03b3-secretase for Familial Alzheimer\u2019s disease. Med Chem Res. 2021;30(7):1321\u20137.","journal-title":"Med Chem Res"},{"issue":"4","key":"4140_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","volume":"54","author":"J-Y Hur","year":"2022","unstructured":"Hur J-Y. \u03b3-Secretase in Alzheimer\u2019s disease. Exp Mol Med. 2022;54(4):433\u201346.","journal-title":"Exp Mol Med"},{"key":"4140_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nbd.2017.03.014","volume":"109","author":"C Condello","year":"2018","unstructured":"Condello C, St\u00f6ehr J. A\u03b2 propagation and strains: implications for the phenotypic diversity in Alzheimer\u2019s disease. Neurobiol Dis. 2018;109:191\u2013200.","journal-title":"Neurobiol Dis"},{"issue":"Pt 3","key":"4140_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awt362","volume":"137","author":"A Rijal Upadhaya","year":"2014","unstructured":"Rijal Upadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamaguchi H, F\u00e4ndrich M, et al. Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease. Brain. 2014;137(Pt 3):887\u2013903.","journal-title":"Brain"},{"issue":"Suppl 2","key":"4140_CR11","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1007\/s00406-013-0449-5","volume":"263","author":"DR Thal","year":"2013","unstructured":"Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J, et al. Pathology of clinical and preclinical Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2013;263(Suppl 2):S137\u201345.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"12","key":"4140_CR12","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.3390\/ijms22126435","volume":"22","author":"M Diociaiuti","year":"2021","unstructured":"Diociaiuti M, Bonanni R, Cariati I, Frank C, D\u2019Arcangelo G. Amyloid prefibrillar oligomers: the surprising commonalities in their structure and activity. Int J Mol Sci. 2021;22(12):6435.","journal-title":"Int J Mol Sci"},{"key":"4140_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/bs.apcsb.2019.06.001","volume":"118","author":"MK Siddiqi","year":"2019","unstructured":"Siddiqi MK, Malik S, Majid N, Alam P, Khan RH. Cytotoxic species in amyloid-associated diseases: oligomers or mature fibrils. Adv Protein Chem Struct Biology. 2019;118:333\u201369.","journal-title":"Adv Protein Chem Struct Biology"},{"issue":"7691","key":"4140_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"9","key":"4140_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353\u201364.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"8","key":"4140_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u0392 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"4140_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"9","key":"4140_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"key":"4140_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s007020070088","volume":"107","author":"N Bogdanovic","year":"2000","unstructured":"Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer\u2019s disease: an immunohistochemical and quantitative study. J Neural Transm. 2000;107:463\u201378.","journal-title":"J Neural Transm"},{"issue":"1","key":"4140_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with Tau and amyloid pathology. Alzheimer\u2019s Dement. 2019;15(1):55\u201364.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"4140_CR21","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1212\/WNL.0000000000201417","volume":"100","author":"A \u00d6hrfelt","year":"2023","unstructured":"\u00d6hrfelt A, Benedet AL, Ashton NJ, Kvartsberg H, Vandijck M, Weiner MW, et al. Association of CSF GAP-43 with the rate of cognitive decline and progression to dementia in Amyloid-Positive individuals. Neurology. 2023;100(3):e275\u201385.","journal-title":"Neurology"},{"issue":"10","key":"4140_CR22","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40520-022-02202-z","volume":"34","author":"Y Lu","year":"2022","unstructured":"Lu Y, Initiative ADN. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment. Aging Clin Exp Res. 2022;34(10):2399\u2013406.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"4140_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13041-024-01136-z","volume":"17","author":"M Sadeghi","year":"2024","unstructured":"Sadeghi M, Azargoonjahromi A, Nasiri H, Yaghoobi A, Sadeghi M, Chavoshi SS, et al. Altered brain connectivity in mild cognitive impairment is linked to elevated Tau and phosphorylated Tau, but not to GAP-43 and Amyloid-\u03b2 measurements: a resting-state fMRI study. Mol Brain. 2024;17(1):60.","journal-title":"Mol Brain"},{"issue":"12","key":"4140_CR24","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/syn.20903","volume":"65","author":"CG Gerin","year":"2011","unstructured":"Gerin CG, Madueke IC, Perkins T, Hill S, Smith K, Haley B, et al. Combination strategies for repair, plasticity, and regeneration using regulation of gene expression during the chronic phase after spinal cord injury. Synapse. 2011;65(12):1255\u201381.","journal-title":"Synapse"},{"issue":"16","key":"4140_CR25","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","volume":"79","author":"PM Doraiswamy","year":"2012","unstructured":"Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-\u03b2 assessed by Florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636\u201344.","journal-title":"Neurology"},{"issue":"3","key":"4140_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA"},{"issue":"3","key":"4140_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA"},{"issue":"12","key":"4140_CR28","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1093\/brain\/awv283","volume":"138","author":"CR Jack Jr","year":"2015","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, et al. Different definitions of neurodegeneration produce similar amyloid\/neurodegeneration biomarker group findings. Brain. 2015;138(12):3747\u201359.","journal-title":"Brain"},{"issue":"6","key":"4140_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol. 2013;74(6):826\u201336.","journal-title":"Ann Neurol"},{"issue":"4","key":"4140_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578\u201386.","journal-title":"Ann Neurol"},{"issue":"3","key":"4140_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"4140_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"2","key":"4140_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biomedicines11020355","volume":"11","author":"S Ribari\u010d","year":"2023","unstructured":"Ribari\u010d S. Detecting early cognitive decline in Alzheimer\u2019s disease with brain synaptic structural and functional evaluation. Biomedicines. 2023;11(2):355.","journal-title":"Biomedicines"},{"key":"4140_CR34","doi-asserted-by":"publisher","first-page":"567537","DOI":"10.3389\/fcell.2020.567537","volume":"8","author":"D Chung","year":"2020","unstructured":"Chung D, Shum A, Caraveo G. GAP-43 and BASP1 in axon regeneration: implications for the treatment of neurodegenerative diseases. Front Cell Dev Biology. 2020;8:567537.","journal-title":"Front Cell Dev Biology"},{"issue":"7\u20138","key":"4140_CR35","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14789450.2020.1831388","volume":"17","author":"S Mazzucchi","year":"2020","unstructured":"Mazzucchi S, Palermo G, Campese N, Galgani A, Della Vecchia A, Vergallo A, et al. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Rev Proteomics. 2020;17(7\u20138):543\u201359.","journal-title":"Expert Rev Proteomics"},{"issue":"12","key":"4140_CR36","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/prca.201500150","volume":"10","author":"J Remnest\u00e5l","year":"2016","unstructured":"Remnest\u00e5l J, Just D, Mitsios N, Fredolini C, Mulder J, Schwenk JM, et al. CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer\u2019s disease. Proteom Clin Appl. 2016;10(12):1242\u201353.","journal-title":"Proteom Clin Appl"},{"issue":"4","key":"4140_CR37","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3233\/JAD-215456","volume":"85","author":"H Zhang","year":"2022","unstructured":"Zhang H, Lyu D, Jia J, Initiative ADN. The trajectory of cerebrospinal fluid growth-associated protein 43 in the Alzheimer\u2019s disease continuum: A longitudinal study. J Alzheimers Dis. 2022;85(4):1441\u201352.","journal-title":"J Alzheimers Dis"},{"key":"4140_CR38","doi-asserted-by":"crossref","unstructured":"La Joie R, Visani A, Baker S, Brown J, Bourakova V, Cha J et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020.","DOI":"10.1126\/scitranslmed.aau5732"},{"issue":"1","key":"4140_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther. 2021;13(1):137.","journal-title":"Alzheimers Res Ther"},{"key":"4140_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. Synaptic Tau seeding precedes Tau pathology in human Alzheimer\u2019s disease brain. Front NeuroSci. 2018;12:267.","journal-title":"Front NeuroSci"},{"issue":"6453","key":"4140_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott B, Simon MM, Hong W, Unger F, Chen-Engerer H-J, Frosch MP, et al. A vicious cycle of \u0392 amyloid\u2013dependent neuronal hyperactivation. Science. 2019;365(6453):559\u201365.","journal-title":"Science"},{"issue":"25","key":"4140_CR42","doi-asserted-by":"publisher","first-page":"10071","DOI":"10.1073\/pnas.1204606109","volume":"109","author":"A Limon","year":"2012","unstructured":"Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABAA receptors in the alzheimer diseased brain. Proc Natl Acad Sci. 2012;109(25):10071\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"4140_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20131685","volume":"211","author":"K Yamada","year":"2014","unstructured":"Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. Neuronal activity regulates extracellular Tau in vivo. J Exp Med. 2014;211(3):387\u201393.","journal-title":"J Exp Med"},{"key":"4140_CR44","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","volume":"77","author":"CA Brunello","year":"2020","unstructured":"Brunello CA, Merezhko M, Uronen R-L, Huttunen HJ. Mechanisms of secretion and spreading of pathological Tau protein. Cell Mol Life Sci. 2020;77:1721\u201344.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4140_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molmed.2005.02.009","volume":"11","author":"FM LaFerla","year":"2005","unstructured":"LaFerla FM, Oddo S. Alzheimer\u2019s disease: A\u03b2, Tau and synaptic dysfunction. Trends Mol Med. 2005;11(4):170\u20136.","journal-title":"Trends Mol Med"},{"key":"4140_CR46","doi-asserted-by":"crossref","unstructured":"Holahan MR. GAP-43 in synaptic plasticity: molecular perspectives. Res Rep Biochem. 2015:137\u2013\u200946.","DOI":"10.2147\/RRBC.S73846"},{"issue":"2","key":"4140_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0166-2236(96)10072-2","volume":"20","author":"LI Benowitz","year":"1997","unstructured":"Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997;20(2):84\u201391.","journal-title":"Trends Neurosci"},{"issue":"8","key":"4140_CR48","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","volume":"95","author":"M Tible","year":"2020","unstructured":"Tible M, Sandelius \u00c5, H\u00f6glund K, Brinkmalm A, Cognat E, Dumurgier J, et al. Dissection of synaptic pathways through the CSF biomarkers for predicting alzheimer disease. Neurology. 2020;95(8):e953\u201361.","journal-title":"Neurology"},{"key":"4140_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-9158-1-18","volume":"1","author":"S Dong","year":"2012","unstructured":"Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer\u2019s disease: a re-evaluation of amyloid cascade hypothesis. Translational Neurodegeneration. 2012;1:1\u201312.","journal-title":"Translational Neurodegeneration"},{"issue":"1","key":"4140_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-023-44374-w","volume":"15","author":"N Franzmeier","year":"2024","unstructured":"Franzmeier N, Dehsarvi A, Steward A, Biel D, Dewenter A, Roemer SN, et al. Elevated CSF GAP-43 is associated with accelerated Tau accumulation and spread in Alzheimer\u2019s disease. Nat Commun. 2024;15(1):202.","journal-title":"Nat Commun"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04140-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:19:11Z","timestamp":1743697151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4140"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04140-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5004381\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review boards of all participating centers approved the study procedure (\n                      \n                      ), and all participants or their authorized representatives provided written informed consent. Ethics approval was obtained from the institutional review boards of each institution involved: Oregon Health and Science University; University of Southern California; University of California\u2014San Diego; University of Michigan; Mayo Clinic, Rochester; Baylor College of Medicine; Columbia University Medical Center; Washington University, St. Louis; University of Alabama at Birmingham; Mount Sinai School of Medicine; Rush University Medical Center; Wien Center; Johns Hopkins University; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; University of California, Irvine; University of Texas Southwestern Medical School; Emory University; University of Kansas, Medical Center; University of California, Los Angeles; Mayo Clinic, Jacksonville; Indiana University; Yale University School of Medicine; McGill University, Montreal-Jewish General Hospital; Sunnybrook Health Sciences, Ontario; U.B.C. Clinic for AD & Related Disorders; and Cognitive Neurology\u2014St. Joseph\u2019s, Ontario; Cleveland Clinic Lou Ruvo Center for Brain Health; Northwestern University; Premiere Research Inst (Palm Beach Neurology); Georgetown University Medical Center; Brigham and Women\u2019s Hospital; Stanford University; Banner Sun Health Research Institute; Boston University; Howard University; Case Western Reserve University; University of California, Davis\u2014Sacramento; Neurological Care of CNY; Parkwood Hospital; University of Wisconsin; University of California, Irvine\u2014BIC; Banner Alzheimer\u2019s Institute; Dent Neurologic Institute; Ohio State University; Albany Medical College; Hartford Hospital, Olin Neuropsychiatry Research Center; Dartmouth-Hitchcock Medical Center; Wake Forest University Health Sciences; Rhode Island Hospital; Butler Hospital; UC San Francisco; Medical University South Carolina; St. Joseph\u2019s Health Care Nathan Kline Institute; University of Iowa College of Medicine; and Cornell University and University of South Florida: USF Health Byrd Alzheimer\u2019s Institute. This study was conducted using ADNI data. The ADNI study is ethically approved and operated in accordance with the Declaration of Helsinki, 1964.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}